Pacritinib

Pacritinib (C28H32N4O3) is an azamacrocycle and a Janus kinase inhibitor, approved as its citrate salt for treating intermediate or high-risk primary or secondary myelofibrosis. It functions as an EC 2.7.10.2 inhibitor, an antineoplastic agent, apoptosis inducer, and anti-inflammatory agent. It belongs to the classes of pyrrolidines, cyclic ethers, and benzenes, and is the conjugate base of pacritinib(1+).